

FAO [REDACTED]
Pfizer UK

Sent by e-mail only: [REDACTED]

13 June 2023

Dear [REDACTED]

Re: Final Appraisal Document — Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]

Thank you for your letter of 9 June 2023, informing NICE of your decision to withdraw your appeal against the above Final Appraisal Document (FAD).

In accordance with NICE's processes, as set out in its appeal process guide [PMG18], my letter of 19 May 2023 set out my initial view of each of the points of appeal you raised in your appeal. I explained that Pfizer had the opportunity to respond to my initial view by 5 June 2023. Had you done so, I would have considered this carefully and provided you with my final decision as to whether each appeal point should be referred to the Appeal Panel.


In the absence of a response to my initial scrutiny letter within the required time frames, I would ordinarily have sent you a further letter confirming the points that would be referred to a hearing (i.e., in this case, those that I had identified as valid and arguable in my letter of 19 May 2023).

However, in this case you have decided to withdraw your appeal, so by this letter I acknowledge your position and confirm that no appeal will proceed.

I have passed your letter to the relevant team within NICE. I understand from them that, as a notice of appeal has been issued, NICE will inform consultees and commentators that the appeal has been cancelled and publish your appeal letter, my initial scrutiny letter of 19 May 2023 and your letter withdrawing the appeal on its website, in line with section 10 of the appeals process guide ("Cancelled appeals").

Should you have any further questions please contact appeals@nice.org.uk

Yours sincerely



Dr Mark Chakravarty

Lead Non-Executive Director for Appeals & Vice Chairman

National Institute for Health and Care Excellence